The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27.
Lois E. Shepherd
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
Suhail M. Ali
No relevant relationships to disclose
Liting Zhu
No relevant relationships to disclose
Kim Leitzel
Research Funding - AstraZeneca; Pfizer
Paul Edward Goss
Honoraria - Novartis; Pfizer
Allan Lipton
Research Funding - AstraZeneca; Pfizer